News & Events about Point Biopharma Global Inc.
POINT Biopharma Global Inc. (NASDAQ:PNT Get Rating) has been assigned a consensus recommendation of Buy from the nine research firms that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target...
Globe Newswire
2 months ago
Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023 INDIANAPOLIS, March 27, 2023 (...
Market News Video
4 months ago
In trading on Monday, shares of POINT Biopharma Global Inc (PNT) crossed below their 200 day moving average of 7.78, changing hands as low as 7.67 per share. POINT Biopharma Global Inc shares are currently trading down about 1.4% on the day...
Shares of POINT Biopharma Global Inc. (NASDAQ:PNT Get Rating) have earned a consensus rating of Buy from the ten analysts that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that...
Globe Newswire
4 months ago
INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the Company or POINT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced management will participate in the following upcoming investor...